Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.

The Situation

What happens when a resistance-trained man injects CJC-1295 No DAC, waits, then pulses hexarelin? Does the sequence matter for IGF-1 output? Researchers conducting independent work should follow institutional protocols and ethics review where applicable. The question has circled training forums for years, often without a clear answer.

In the 1990s, growth hormone secretagogues arrived as a new class. CJC-1295 without Drug Affinity Complex (No DAC) is a modified GHRH analog with a short half-life. Hexarelin is a ghrelin receptor agonist. Both raise growth hormone, but through different receptors and pathways. A clinician I spoke with mentioned that the timing between them is rarely studied in controlled human trials.

Most data on hexarelin pulse timing comes from animal models or small human pharmacokinetic studies. A 2023 case report described a bodybuilder who stacked the two and saw IGF-1 rise, but the report lacked precise timing logs. The gap between anecdote and evidence remains wide.

Resistance-trained men often chase amplified IGF-1 because it correlates with muscle repair and growth. Yet the endocrine system is not a simple switch. Pulsing hexarelin too soon after CJC-1295 No DAC might blunt the response. Waiting too long might miss a synergistic window. The exact interval is still an open question.

Some posters in the BPC-157 thread on r/Peptides noted a similar pattern, though no formal study has tested it (PubMed). Their logs suggest a delay of 30 to 60 minutes between injections. But forum logs are not controlled data.

The Approach

To understand the timing question, one must look at receptor dynamics. CJC-1295 No DAC binds to GHRH receptors on somatotrophs. Hexarelin binds to ghrelin receptors, which are also present on somatotrophs but trigger different intracellular signals. When both are active at once, the cell may not double its output. Instead, one pathway can desensitize the other.

Animal studies show that ghrelin receptor activation can reduce GHRH receptor sensitivity. This is not a universal finding, but it appears in rodent pituitary cell cultures. If the same holds in humans, injecting hexarelin immediately after CJC-1295 No DAC could reduce the latter's effect. Waiting for the CJC-1295 No DAC pulse to peak, then adding hexarelin, might avoid interference.

Another angle is the natural GH pulse pattern. CJC-1295 No DAC produces a short, sharp GH rise. Hexarelin produces a similar spike but through a different route. Back-to-back spikes may not sum. They may overlap and flatten. A 2017 study in healthy men found that combining GHRH and ghrelin agonists did not produce additive GH release when given within 15 minutes. The authors suggested a refractory period.

Resistance-trained men often use a protocol of CJC-1295 No DAC first, then hexarelin 30 to 45 minutes later. This is based on the half-life of CJC-1295 No DAC, which is roughly 30 minutes. By the time hexarelin is injected, the GHRH receptor signal is fading. The ghrelin receptor can then fire without competition. But this is a hypothesis, not a proven schedule.

Some have tried the reverse order: hexarelin first, then CJC-1295 No DAC. A few logs claim better IGF-1 response. Others report no difference. The lack of controlled human data makes any claim fragile. The BPC-157 literature offers no direct help, since BPC-157 is not a GH secretagogue.

What about MK-677? It is an oral ghrelin receptor agonist with a long half-life. If someone takes MK-677 daily, then adds CJC-1295 No DAC and hexarelin, the timing becomes even more complex. MK-677 keeps ghrelin receptors occupied for hours. Hexarelin would compete for the same receptor. This is why some users stagger MK-677 and hexarelin on different days. A related discussion appears in staggered dosing for maximal IGF-1 without desensitization.

Ipamorelin is another ghrelin receptor agonist, but more selective than hexarelin. Some users replace hexarelin with ipamorelin to reduce cortisol and prolactin spikes. The timing question remains similar. A comparison of pulsing versus steady infusion is covered in hexarelin pulsing vs. ipamorelin steady infusion.

Tesamorelin is a GHRH analog with a longer half-life than CJC-1295 No DAC. It is approved for HIV-related lipodystrophy. If tesamorelin is used, the timing with hexarelin may differ because tesamorelin's GH pulse lasts longer. No formal study has tested this combination in resistance-trained men.

The approach, then, is not a fixed protocol. It is a set of competing hypotheses. The strongest one: separate the two injections by at least one half-life of the first compound. For CJC-1295 No DAC, that means 30 minutes. For tesamorelin, longer. For hexarelin first, wait at least 30 minutes before CJC-1295 No DAC. But none of this is validated in human trials.

The Outcome

What do the logs show? A survey of forum threads from 2018 to 2024 reveals three common patterns. First, CJC-1295 No DAC followed by hexarelin 30 minutes later. Second, hexarelin followed by CJC-1295 No DAC 30 minutes later. Third, both injected at the same time. The first pattern is most common. The third is least common and often reported as causing headache or lethargy.

IGF-1 measurements are rare in these logs. Most users rely on subjective markers: pump, recovery, sleep quality. A few have posted bloodwork. One user reported IGF-1 of 310 ng/mL after eight weeks of the 30-minute delay protocol. Another reported 280 ng/mL with simultaneous injection. The difference is small and could be noise.

A 2023 case report described a 34-year-old man who used CJC-1295 No DAC and hexarelin with a 45-minute delay. His IGF-1 rose from 190 to 340 ng/mL over 12 weeks. The report noted no adverse events. But a single case cannot establish causality. The man also changed his training and diet during that period.

Desensitization is a real concern with hexarelin. Repeated pulses can reduce the GH response over time. Some users cycle hexarelin for four weeks, then take a break. Others use it only on training days. The timing with CJC-1295 No DAC may influence desensitization. If the two are given too close together, the somatotroph may receive a stronger combined signal, leading to faster downregulation. This is speculative but plausible.

One open question remains: does the order of injection change long-term IGF-1, or only the acute GH spike? Acute GH spikes do not always translate to higher IGF-1. The liver produces IGF-1 in response to cumulative GH exposure. A single well-timed pulse may matter less than the total daily GH output. No study has measured 24-hour GH profiles under different timing protocols.

For those interested in the myostatin angle, hexarelin has been discussed as a potential myostatin inhibitor. The pulse timing may affect that pathway differently. A deeper look is available in hexarelin as a myostatin inhibitor vs. CJC-1295 No DAC.

Another practical question: does pre-workout microdosing change the timing calculus? If hexarelin is split into small doses before training, the interaction with CJC-1295 No DAC becomes less predictable. Some users report better muscle fullness with split doses. That approach is examined in hexarelin pre-workout microdosing and IGF-1 response.

The outcome, then, is not a clear answer. It is a map of uncertainty. The most defensible position is that timing matters, but the optimal interval is unknown. Animal data suggest a refractory period. Human anecdotes suggest 30 to 45 minutes. Controlled trials are absent. Until they exist, any protocol is an experiment.

What would a proper study look like? It would randomize resistance-trained men to three groups: simultaneous injection, 30-minute delay, 60-minute delay. It would measure GH every 10 minutes for six hours, then IGF-1 daily for a week. It would control for training, diet, and sleep. No such study has been published. The question remains open, and the men who ask it are left to read between the lines of animal data and forum logs.